Gastroenterology

Caris Life Sciences™ brings academic-caliber gastrointestinal (GI) pathology services to patients and their physicians with state-of-the-art laboratories, world-class physicians, and unsurpassed service. Caris is integrating new molecular technologies into daily practice and ensuring that physicians and patients have access to the most informative and relevant diagnostic information available.

Caris' GI pathologists are all subspecialty trained in gastrointestinal pathology, and include nationally known leaders in the field who hold and have held professorship positions at leading academic institutions such as Johns Hopkins, Harvard (Brigham and Women's and Beth Israel), Cleveland Clinic, Mayo Clinic, M.D. Anderson, Duke, Cornell, University of Texas, Memorial Sloan-Kettering Medical Center and many others. These distinguished pathologists and their colleagues have published over 1,550 peer-reviewed research studies and over 150 textbooks and book chapters, and regularly present research at the major national meetings for gastroenterologists and pathologists.

At Caris, an expert team carefully scrutinizes every biopsy under the microscope to render an accurate diagnosis for each patient. Caris also uses molecular testing to help ensure the precision of these diagnoses and may help guide the most appropriate treatment. The company's  cancer molecular profiling tool, Caris Target Now, combines a powerful array of tests that may help provide information that assists physicians and patients with therapeutic choices. The company's commitment to providing the most current, evidence-based testing is exemplified in its testing for defects in DNA mismatch repair gene function that can identify patients with certain types of genetic colorectal cancer. These patients require different treatment and follow-up, and their families can benefit from this critical information (Read more about IHC MMR testing here).

Caris is also focused on the development of a highly-accurate and precise blood-based diagnostics platform to address unmet clinical needs across the gastrointestinal cancer spectrum — from screening and diagnosis to prognosis and therapeutic guidance — enabling physicians to provide patients with precise and effective treatment.

Caris is the world’s largest outpatient GI pathology practice, examining well over 2,500 GI biopsies every day. This unparalleled access to biopsy samples provides Caris' pathologists with unique research and learning opportunities to evaluate unusual cases as well as to characterize common diseases in ways not previously possible. The Caris commitment to ongoing learning is manifested through daily slide-review conferences, monthly didactic and journal review conferences, rigorous quality assurance, and continuous review of the company's diagnostic terminology and criteria.